Latest news
4 April 2024
University of Liverpool to use Touchlight’s rapid enzymatic dbDNA in fully personalised neoantigen cancer vaccine clinical study
The UK’s Medical Research Council is funding a 10-patient Phase I study to deliver rapid personalised treatment for lung cancer patients. Hampton, UK – 3 April 2024 – Touchlight, a CDMO enabling the development of genetic medicines with its enzymatic doggybone DNA (dbDNA™) technology, today announced an agreement with University of Liverpool for the use of … Continued
28 March 2024
Touchlight awarded tender to supply enzymatic dbDNA to CPI’s RNA Centre of Excellence
Touchlight, an innovation-driven CDMO enabling the development of genetic medicines with its doggybone DNA (dbDNA™) technology and leaders in enzymatic DNA production, is delighted to announce that it has been awarded a tender to deliver enzymatic DNA as part of CPI’s tender process for the establishment of its RNA Centre of Excellence. CPI, a leading … Continued
21 November 2023
Touchlight’s enzymatic doggybone DNA used in the manufacture of Versameb’s VMB-100 for first-in-human clinical study
Based on prior manufacturing agreement that encompasses usage of Touchlight’s doggybone DNA (dbDNA™) to manufacture clinical supply of VMB-100 for Phase 2a trial to treat stress urinary incontinence (SUI). Hampton, UK – 21 November 2023 – Touchlight, a CDMO enabling the development of genetic medicines with its enzymatic doggybone DNA (dbDNA) technology, today announced that the Company … Continued
24 May 2023
Touchlight completes expansion, creating one of the world’s largest DNA manufacturing facilities in London, UK
Facility will have capacity that exceeds today’s global plasmid DNA demand and can enable commercialisation of genetic medicines. Transformation of Grade II-listed Victorian waterworks on the River Thames in Hampton, London. Supplying many of the top biopharmaceutical companies in the world to dramatically enhance their ability to develop genetic medicines. Expansion follows recent acceptance of … Continued
18 April 2023
20Med Therapeutics and Touchlight to collaborate on novel vaccine delivery platform project
Enschede, The Netherlands, and Hampton, UK – April 18, 2023 – 20Med Therapeutics, a leader in non-viral delivery and development of gene therapies and vaccines, and Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, today announced that both parties will collaborate on establishing a novel vaccination platform that combines … Continued
29 March 2023
Touchlight secures government grant to support its £14m investment in scale-up DNA manufacturing
Hampton, UK, 29 March 2023 – Touchlight, a CDMO pioneering enzymatic DNA production to enable genetic medicines, today announced that it has secured a grant from the Department for Science, Innovation and Technology to support the acceleration of its £14m scale-up DNA manufacturing programme. The grant comes from the £277 million in joint government and … Continued
28 February 2023
Touchlight announces first FDA clearance of an IND utilising doggybone DNA
Enzymatic doggybone DNA material used in GMP production of a cell therapy by a US-based client. Major landmark demonstrates the clinical adoption of Touchlight’s proprietary technology across modalities. Hampton, UK, 28 February 2023 – Touchlight, a CDMO pioneering enzymatic DNA production to enable genetic medicines, today announced the first FDA clearance of an Investigational New Drug (IND) … Continued
24 January 2023
FDA accepts Drug Master File, signifying a new milestone for Touchlight’s enzymatic doggybone DNA technology
Drug Master File simplifies the U.S. regulatory process for utilising Touchlight’s doggybone DNA and accelerates regulatory filings. doggybone DNA is the first enzymatic DNA platform with a Drug Master File, representing a significant step towards regulatory adoption. Hampton, UK, 24 January 2023 – Touchlight, a biotechnology company pioneering enzymatic DNA production to enable genetic medicines, today announced … Continued
7 December 2022
Touchlight and Odimma Therapeutics announce clinical material supply agreement to develop personalised cancer therapy utilising doggybone DNA
Touchlight and Odimma have entered into an agreement to develop and supply clinical material for Odimma’s neoantigen program Hampton, UK, 7 December 2022 – Touchlight, a biotechnology company pioneering enzymatic DNA production to enable genetic medicines, today announces a development and supply agreement with Odimma Therapeutics, a French biotech company focusing on personalised cancer immunotherapy. … Continued
29 November 2022
Touchlight receives grant to advance rapid, scalable and thermostable doggybone DNA vaccine platform
Funding from the Bill & Melinda Gates Foundation will build on preclinical data showing the potential of nanoparticle-formulated doggybone DNA to deliver strong antibody titres and strong T cell responses. Hampton, UK – 29 November 2022 – Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, is furthering pre-clinical development … Continued
15 November 2022
Touchlight signs license agreement with Voyager for use of Touchlight’s DNA technology in Voyager’s capsid discovery platform
Hampton, UK, 15 November 2022 – Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, today announces a patent license agreement with Voyager Therapeutics, Inc., a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids. Under the license agreement, Voyager gains rights to Touchlight’s DNA technology for use in … Continued
6 September 2022
Lonza and Touchlight collaborate on end-to-end mRNA offering
Collaboration expands Lonza’s end-to-end offering for mRNA manufacturing with additional, differentiated source of DNA raw material, Touchlight’s doggybone DNA (dbDNA). Touchlight provides synthetic DNA through a cell-free enzymatic process, with advantages of speed, quality, capacity, and scalability. Customers can gain access to Touchlight’s dbDNA as an integral part of Lonza’s offering, benefiting from end-to-end mRNA … Continued